Evaluation of homologous recombination repair status in metastatic prostate cancer by next-generation sequencing and functional tissue-based immunofluorescence assays
Sara Arce‐Gallego(Hebron University), Joaquı́n Mateo(Royal Marsden NHS Foundation Trust)
Cited by 1
Related Papers
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
|Annals of Oncology|2018|774
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
|The Lancet Oncology|2019|643
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
|Cancer Discovery|2017|422